Antibody Discovery

Antibody humanization

Murine antibodies are often prone to induce immune reactions in humans, which might affect the safety and efficacy of antibody therapy, so antibody humanization is necessary during early drug discovery.
Antibody humanization,which means taking advantage of gene engneering methods, to replace part of original murine amino acid sequence with human-origin sequences in order to minimize the murine origin of the non-binding site, finally retain or even improve the original affinity and specificity of the antibody.

OPM can deliver humanized antibodies as fast as 3 weeks, and can seamlessly connect with downstream services such as druggability assessment.

Transient transfection expression

Mammalian cells can rapidly express antibodies or recombinant proteins in a short time through efficient transient transfection. OPM transient expression platform provides correctly constructed high expression vector and high performance transient medium, with high-quality purification and complete QC testing service, which could quickly and efficiently produce antibodies or recombinant proteins for the client.

• Extensive experience in expressing various types of proteins

• Customized services

• Fast delivery and high-quality

Evaluation of drug efficacy

Druggability refers to the developability, stability and safety of a molecule. Through DNA sequence assessment, initial characterization analysis, molecular stability assessment and pre-formulation studies services, OPM developability assessment platform helps customers to quickly screen candidate molecules, and reduce the cost of later process development and risks in the clinical stage, and facilitate rapid drug application.

OPM has 20+ developability assessment experience for antibody drugs, and the lead molecules screened through the developability assessment have 100% success rate in the follow-up CMC development.